WntResearch and Collective Minds Radiology sign agreement for quality assurance of clinical study
WntResearch and Collective Minds Radiology announce that the companies have signed an agreement to quality assure data reading in the ongoing phase 2 study of the drug candidate Foxy-5. The collaboration increases the precision of the evaluation of the treatment effect in the study.
Collective Minds Radiology, CMRAD, is a health-tech company that has developed a cloud-based platform for research and healthcare purposes. The CMRAD platform will provide the base for central independent expert reading of diagnostic imaging performed in patients included in the study. The clinics will share diagnostic imaging in the CMRAD platform, which will then be evaluated by two radiologists. The main responsible reader will be Lennart Blomqvist, Professor and research group leader in diagnostic radiology at the Department of Molecular Medicine and Surgery at Karolinska Institutet and also co-founder of CMRAD.
“It feels very rewarding to be able to contribute and design the data collection with radiological examinations in the continued study. With my experience in radiology in oncologic clinical trials, I know how important this is. It will be very interesting to be involved in evaluating the treatment effect on imaging, says Lennart Blomqvist.
The studies are performed on colon cancer patients who are enrolled in the NeoFox Phase 2 clinical trial, which is a proof-of-concept study conducted by WntResearch. Positive ad hoc observations allowed the design to be adjusted, providing significant benefits in terms of time and cost savings. The new study design was approved during summer 2023 by the relevant regulatory authorities and the first patient was enrolled in the redesigned study in mid-October.
The treatment effect of Foxy-5 is assessed based on local tumor spread and spread to nearby lymphatic vessels, which in turn is expected to indicate a reduced risk of recurrence and distant metastases. These parameters will be evaluated by computed tomography at diagnosis and at surgery, and by microscopic examination of removed tumors and lymph nodes. The clinical study is open, randomized and will compare treatment with Foxy-5 to patients in a control group.
“Through the collaboration, we centralise the imaging assessment, which reduces the variability and increases the quality. In the updated study design, we have optimised the possibilities to measure the tumour both at diagnosis and at surgery. Ensuring the precision of these measurements is of great importance for the reliability of the study results”, says Pernilla Sandwall, CEO of WntResearch.
For further information:
Pernilla Sandwall, CEO
WntResearch is an oncology biotech company that develops new therapies to counteract the development of cancer metastases. The company’s research is focused on studying the endogenous protein WNT5A, which has been shown in scientific studies to affect the ability of tumor cells to move and spread in the body. WntResearch’s drug candidate Foxy-5 is a peptide that mimics the function of WNT5A with the aim of reducing the mobility and spread of cancer cells and thereby preventing metastases from occurring. Although today’s cancer treatment has become more effective, there are no effective ways to prevent the occurrence of metastases that cause about 90 percent of all cancer-related deaths. Foxy-5 has a unique mechanism of action and has shown a good safety profile with few side effects in two clinical phase I studies. The safety and efficacy of Foxy-5 is now being evaluated in the ongoing Phase 2 clinical trial NeoFox in patients with stage II-III colon cancer. WntResearch’s registered office is in Malmö and the company is listed on Spotlight Stock Market. For more information see: www.wntresearch.com
About Collective Minds Radiology
Collective Minds Radiology is a Swedish healthtech startup founded in Stockholm in 2017. We develop and deliver a cloud-based collaboration platform for healthcare with access to data, and human and digital expertise. Together with our partners and customers we offer products and services within medical image research, clinical consultation and education. For more information, visit about.cmrad.com